Abortion
¡@

INTRODUCTION

¡@

Background: In the US and worldwide, elective termination of pregnancy remains common. Accurate statistics have been kept since the enactment of the 1973 Supreme Court decisions legalizing abortions. Since then, approximately 1.3-1.4 million abortions have been performed annually in the US, and worldwide some 20-30 million legal abortions are performed annually, with another 10-20 million abortions performed illegally . Illegal abortions are unsafe and account for 13% of all maternal mortality and serious complications. Death from abortion is almost unknown in the US or in other countries where abortion is available on demand.

In spite of the introduction of newer, more effective, and more widely available contraceptive methods, more than one half of the 6 million pregnancies occurring each year in the US are termed unplanned by the women who are pregnant. Of these pregnancies, approximately one half end in elective terminations. Abortion is still one of the most common medical procedures performed in the US each year, and more than 40% of all women will have a pregnancy terminated by abortion at some time in their reproductive lives. Each year in the US, almost 3% of all women of reproductive age terminate their pregnancies. While women of every social class seek terminations, the typical woman who terminates her pregnancy is young, white, unmarried, and poor.

The development of more advanced surgical techniques has allowed for safe second trimester terminations and, statistically, more of these have been performed. The Food and Drug Administration (FDA) recently has given approval to Mifeprex (mifepristone, RU-486) for medical abortions. Multiple regimens for medical terminations using medications approved by the FDA for indications other than termination of pregnancy have come into use. The lack of abortion providers to perform surgical terminations has led to the popular belief that individuals not willing or not skilled enough (through training or licensure) to perform surgical terminations will be willing to prescribe medications for medical termination. This may be difficult to track statistically but may actually lead to an increased number of abortions in the US.

A variety of medical, social, ethical, and philosophical issues affect the availability of and restrictions on abortion services in the US. An understanding of the laws (enacted, enjoined, and pending) on local and federal levels is important to providers, and these legal ramifications are reviewed in this chapter as well .

Abortion postoperative care often is provided at sites that did not perform the termination of pregnancy, and strategies for follow-up care for women whose pregnancies have been terminated are important for all providers of primary care for women.

¡@

Surgical termination

The development of accurate over-the-counter (OTC) pregnancy tests allows for the diagnosis of pregnancy 1-2 weeks after conception. Terminations performed in this very early time frame have been termed "menstrual extractions,?a historical reference to a time when, prior to the availability of accurate pregnancy tests, providers made the presumptive diagnosis based on clinical history and performed extremely early suction evacuations without histologic tissue confirmation, allowing for maximum confidentiality for both patient and provider.

Abortions performed prior to 9 weeks from last menstrual period (LMP) (7 wk from conception) are performed either surgically or medically. From 9 weeks until 14 weeks, an abortion is performed by a dilatation and suction curettage procedure. After 14 weeks, surgical abortions are performed by a dilatation and evacuation procedure. After 20 weeks of gestation, abortions can be performed by labor induction, prostaglandin labor induction, saline infusion, hysterotomy, dilatation and extraction, or intact dilatation and extraction. Most abortions are performed in an ambulatory office setting under local anesthesia with or without sedation.

Medical abortion

Medical abortion is a term applied to a medication-induced elective abortion. This can be accomplished with a variety of medications administered either singly or in succession. Medical abortion has a success rate that ranges from 75-95%, with about 2-4% of failed abortions requiring surgical abortion and about 5-10% of incomplete abortions, depending upon the stage of gestation and the medical products used. For a review of multiple studies see Kahn et al 2000. Patients who select a medical abortion express a slightly greater satisfaction with their route of abortion and, in the majority of cases, express a wish to choose this method again should they have another abortion. Research needs to be done to more clearly establish which protocol is best, which medications are preferable, and how successfully women and adolescents can diagnose a complete versus an incomplete abortion.

Although a critical shortage of providers to provide surgical abortions exists, in a recent study by Koenig et al providers who do not perform surgical abortions have indicated a willingness to provide medical abortions.

Medical abortions can provide some measure of safety in that they eliminate the risk of cervical lacerations and uterine perforations. Some patients require an emergency surgical abortion, and for safety concerns, patients undergoing medical abortions need access to providers willing to perform an elective termination.

The in September of 2000 the FDA approved mifepristone (RU-486) for use in a specific medical regimen that includes misoprostol administration for those who do not abort with mifepristone alone. Methotrexate and misoprostol are approved drugs for other indications that can be used for medical termination of pregnancy. Additional research will determine exactly which regimen is the best for medical abortions.

Medical abortions have additional management issues for patients and clinicians. The process involves bleeding, often heavy, which must be differentiated from hemorrhage. Regardless of the amount of tissue passed the patient must be seen for evaluation of the completeness of the process.

¡@

Frequency:
¡@

• In the US: Abortion statistics are available from a variety of sources, including, the CDC, the Alan Guttmacher Institute, and the National Abortion Federation. Information and specific instructions regarding state requirements for abortion reporting are available from vital statistics offices in each state health department. Comprehensive statistical information is regarded as important in ensuring the utmost in patient safety (Centers for Disease Control and Prevention).

  In 1996, approximately 20 women for every 1000 women aged 15-44 years had an abortion, and for every 1000 live births, approximately 325 abortions were performed . In the past 20 years, considerable progress has been made in the technology used for second trimester abortion. This and the social milieu of abortion have led to more women seeking terminations later in pregnancy. For the current facts regarding abortions performed in various states at various times in the pregnancy.

• Internationally: Globally, abortion mortality accounts for at least 13% of all maternal mortality. New estimates are that 50 million induced abortions are performed each year in developing countries, with some 20 million of these performed unsafely because of conditions or lack of provider training. Maternal mortality is 600,000 per year due to pregnancy-related causes, and 99% of these deaths are in developing countries.

Mortality/Morbidity: The safety of abortion is well established, with infection rates less than 1%, and less than 1 per 100,000 mortalities occurs from first-trimester abortions. At every gestational age, elective abortion is safer for the mother than carrying a pregnancy to term.

Race: In 1996, of the women who obtained legal abortions, 59.1% were white, 35, 2% were black, and 5.7% were other (of the other, 16.1% were Hispanic).

CLINICAL

¡@

History: Most terminations of pregnancy are performed after a brief and targeted gynecologic and obstetric history. Providers should obtain information about any prior pregnancies and information regarding any treatment or care during this pregnancy. The history taking also should focus on prior gynecologic disease with particular attention to previous or current sexually transmitted infections (STIs). Information regarding medical history that might be important includes a history of diabetes, hypertension or heart disease, anemia or bleeding disorders, or previous gynecologic surgery. A history of active medical problems may mean that the patient needs to be medically stabilized prior to the abortion or have the procedure performed in a facility that can handle special medical problems.

• Maternal indications for abortion

• With advances in perinatal care, few medical contraindications to pregnancy exist. Perinatologists, obstetricians, and abortion counselors prefer to put the risks in the context of statistical likelihood of complications and then let the patient make her final decision.

• Women take on less risk, regardless of health or gestational age, to terminate a pregnancy than to continue to term. These abortions have been termed therapeutic abortions.

• Maternal medical conditions that carry significant risks in pregnancy include severe diabetes with retinopathy, cardiac or renal complications, advanced cardiac disease, renal failure, sickle cell disease, autoimmune disease, and psychiatric disease.

• Cardiac conditions that still carry maternal mortality rates of 5-15% include severe mitral stenosis, coarctation of the aorta, uncorrected tetralogy of Fallot (TOF), aortic stenosis, myocardial infarction history, and presence of artificial heart valves. Greater mortality rates have been reported in women with coarctation of the aorta with vascular involvement, pulmonary hypertension, Marfan syndrome with aortic involvement, and myocardial infarction in pregnancy.

• Nondirective counseling can help a woman select her choice.

• Fetal indications for abortion

• Fetal conditions that are incompatible with life include anencephaly, trisomy 13, trisomy 18, renal agenesis, thanatophoric dysplasia, alobar holoprosencephaly, and some hydrocephalic cases.

• Many hypoplastic cardiac conditions also are incompatible with life. However, with cardiac transplantation, some infants now can survive birth with these defects.

• Anomalous conditions that are common and encountered in abortion counseling include most fetal cardiac anomalies, trisomy 21, open and closed neural tube defects, limb, face, or cleft abnormalities, esophageal or duodenal atresia, chest and abdominal wall defects, cystic kidneys or hydronephrosis, intracranial calcifications suggestive of viral disease, or diaphragmatic defects.

Physical:

• A brief physical examination usually is conducted prior to an abortion procedure. The focus is on dating the pregnancy, ensuring the absence of other gynecologic pathology, particularly STIs, and assessing the patient's suitability for an operative procedure under local sedation.

• Note any vaginal or cervical discharge, the nature of the cervix, and any lesions. Document the presence or absence of any ovarian pathology.

• If the patient is going to have general anesthesia, a typical screening preoperative physical can be performed.

DIFFERENTIALS

¡@

Anemia
Cervicitis
Early Pregnancy Loss
Ectopic Pregnancy
Missed Abortion
Pelvic Inflammatory Disease
¡@

Other Problems to be Considered:

Bacterial vaginosis
Cervical dysplasia or neoplasia
Ovarian masses
Uterine fibroids
Uterine anomalies
Multifetal gestations
Fetal anomalies
Maternal illnesses
Maternal allergies
Bleeding or clotting disorders
Grand multiparity
Cervical incompetence
Sexual Assault
Psychological trauma
Bacterial endocarditis prophylaxis
Benign Lesions Of The Uterine Corpus

WORKUP

¡@

Lab Studies:
¡@

• Preabortion workup

• Pregnancy tests are used to confirm the presence of a pregnancy, and home tests are reliable enough to accept their results in some cases.

• Hemoglobin (Hb) or hematocrit (Hct) levels always are assessed. Full CBC is optional but may be indicated if abnormalities are detected with the Hb or Hct test.

• STI screening typically includes a test for gonorrhea culture (GC) or chlamydial test (CT). Screening for other STIs, such as syphilis or HIV disease, is usually prohibitively expensive, but patients who are found to have GC or CT should be offered these tests.

• Rh typing is always performed. ABO typing is optional.

• Use of human chorionic gonadotropin titers

• Human chorionic gonadotropin (HCG) titers are helpful in performing very early terminations, to establish the completeness of an abortion postoperatively in cases of a persistent positive urinary pregnancy test, or to establish the presence of an ectopic pregnancy. In medical abortion protocols they can also be used to establish the arrest of viability of a pregnancy, or to establish the completeness of a medical abortion.

  Titer resolution is different between surgical and medical abortions. The titer should decrease to approximately 64% of its preabortion value within 24 hours of misoprostol being administered in medical abortion protocols. By 2 weeks, the titers should have dropped 99%.

• If an abortion is being performed prior to 5 weeks from LMP, titers preoperatively can be very useful. Managing most abortion procedures without an HCG titer is within the standard of care.

• Wet preparations

• Vaginal wet preparations, pH testing, or urine dipstick analysis usually are performed for standard indications.

• If a woman is discovered to have a concomitant infection, it may need to be treated before she has the abortion.

Imaging Studies:
¡@

• Ultrasonography is invaluable but not always used in first trimester terminations. Standard of care demands that second trimester terminations be evaluated preoperatively with sonography. Documenting uterine abnormalities is important because failed terminations can occur in patients with double uterus or ectopic pregnancies.

TREATMENT

¡@

Medical Care: Once the pregnancy has been confirmed, gestational age has been established, and the patient has decided to abort, the procedure offered typically reflects the patient's stage of gestation. Early abortions can be accomplished medically or surgically, but most facilities do not have the technical ability or the protocols established to offer medical abortions. Therefore, most abortions are performed surgically.

• Preoperative care of patients undergoing surgical abortion

  ¡@

  • Women often travel far for their abortion procedure and feel comfortable completing the preoperative preparation in a short office visit. In states where laws require waiting periods, this can be done in stages.

    ¡@

  • The assessment process only involves a targeted history, physical, laboratory work, and ultrasound evaluation (including dating of the pregnancy, if indicated) followed by a counseling session.

    ¡@

  • Second trimester pregnancy preparation is more difficult. It is almost impossible to prepare the cervix in less than 24 hours, but the basic assessment process is identical.

    ¡@

  • Ultrasound examinations should involve a more extensive examination looking specifically for obvious fetal anomalies.

    ¡@

  • Some centers also offer an intra-amniotic injection of digoxin 1 mg, which ceases fetal cardiac activity and has very low transplacental medication leakage, so it has been shown to be safe for the mother. This ensures fetal death prior to fetal expulsion regardless of method of second trimester abortion.

• Abortion counseling

  ¡@

  • Most abortion counseling focuses on the decision-making process, the options for continuing the pregnancy, medical issues of the pregnancy, information regarding the pregnancy itself, full disclosure of the risks of continuing to term, information and options for the technique of the abortion procedure, and, finally, information regarding a contraceptive decision. Now that medical protocols are becoming more widely available, the risks and benefits of both medical and surgical abortions should be reviewed.

    ¡@

  • The counseling process is aimed primarily at the woman herself, as well as those she chooses to have involved. Studies indicate that males are involved in more than 40% of the decisions, but only scant research has been done on male involvement in the process. Some women can reach a decision quickly; others take longer to decide. The counseling process should offer referrals for those who need ongoing support.

    ¡@

  • Of utmost importance is to ensure that the patient has had enough time to consider her options and that she is not being coerced into her decision.

    ¡@

  • Many strategies can be used in the counseling session. Open-ended questions bring out issues that are pertinent to the woman and encourage meaningful exchange of dialogue. The patient's emotions should be validated, and the counselor should encourage the client to explore her feelings in more depth. Health care providers and counselors may not have the time or the expertise to devote themselves to lengthy sessions, and not all women are able to complete the process in a day if these issues need to be explored before the abortion procedure.

    ¡@

  • Some state laws may apply to the counseling process. Some states have mandatory waiting times between the information session and the actual abortion, other states require family or parental notification, and some states mandate that certain subjects be covered. Laws directed towards the providers usually also exist. Providers have an obligation to find out about their local laws and to comply with them.

• First and second trimester medical abortion

  ¡@

  • First trimester terminations are accomplished medically with misoprostol alone, methotrexate-misoprostol combination regimens, or Mifeprex (RU-486) with or without misoprostol. Other prostaglandins are in use in other countries.

    ¡@

  • Medical abortions are indicated for women who consent to a medical abortion but also are willing to undergo a surgical abortion if the medical abortion fails. Gestational age usually is less than 42-49 days, but many protocols including up to 63 days from LMP are in the literature. Literature has also documented safety of medical abortion protocols between 11-13 weeks is accumulating. Only scant reports exist of continuing pregnancies after misoprostol, but the current data do not suggest a teratogenic action of misoprostol exposure during pregnancy.

    ¡@

  • Contraindications to medical abortion vary depending upon the regimen selected. Contraindications to mifepristone, include serious medical problems, such as cerebrovascular or cardiovascular disease, severe liver, kidney or pulmonary disease, preoperative anemia (<10 mg/dL), undiagnosed ectopic pregnancy allergies contraindications to prostaglandin use, active uterine bleeding, or large uterine leiomyomata.

    ¡@

  • The Mifeprex/misoprostol appointment schedule is as follows: On day 1, Mifeprex 600 mg PO is administered in the office. On day 3, misoprostol 400 mcg PO or vaginally is administered at home and with 4 hours of observation. Between days 12 and 20, the patient returns to the office to determine if the abortion has been completed. If it has not, repeat misoprostol is administered or the patient may undergo a surgical abortion.

    ¡@

  • The methotrexate/misoprostol regimen is similar. Methotrexate is injected on day 1. On days 6-7, misoprostol is taken at home vaginally, and the patient returns to the office on day 8 to determine if the abortion has taken place. Misoprostol can be repeated and the patient monitored, or surgical abortion may be completed.

• Prostaglandin-induced second trimester abortion

• Prostaglandin can be administered vaginally, orally, or via extraovular or intra-amniotic infusion. The intra-amniotic route was associated with greater rates of uterine rupture, although rarely, and has been abandoned largely in favor of the safety and technical ease of oral or vaginal administration.

  ¡@

• In a recent comparison study by Perry of intra-amniotic 15-methyl-prostagalin F2-alpha and intravaginal misoprostol, the mean evacuation time was slightly less in the intra-amniotic group, and the rate of success by 24 hours was higher in the intra-amniotic group. The total complete abortion rate and incidence of severe effects were similar in both groups.

• Saline-induced abortion: Twenty years ago, saline-induced abortion was the only viable means of aborting a mid–second trimester pregnancy, and most of the literature regarding this technique is from that era. The process was long, laborious, had some potentially serious adverse effects, and has been abandoned for the greater maternal comfort offered by the dilatation and extraction procedures that subsequently have been developed. However, dilatation and extraction procedures are risky in the hands of inexperienced providers or providers who do not perform the procedures often enough to maintain competency. In these circumstances, the saline induced abortion can be safely used.

Surgical Care: Documentation is an important part of the surgical procedure. Preoperatively prepared standard operative reports are the standard of care and should include documentation of several important features including the patient's anatomical assessment (including uterine size), the procedure and instruments used (including the size of the dilators and the cannula used), the amount of blood loss, and the amount of tissue obtained.

• Cervical dilatation and preparation: Women having first trimester terminations, particularly those at less than 10 weeks?gestation, rarely need preoperative cervical preparation. For those in the later part of the first trimester, preoperative dilatation with laminaria or medical treatment with prostaglandins is helpful and should be at the discretion of the provider performing the abortion. In the second trimester or beyond, the cervix needs preparation. Forceful cervical dilatation can lacerate the cervix, which can cause significant bleeding or in rare cases lead to cervical incompetence.

  ¡@

  • Laminaria: Laminaria japonicas are small sticks of presterilized seaweed that can be inserted preoperatively to dilate the cervix. They are generally thought to do this by absorbing water and swelling mechanically. Some believe that other hormonal mechanisms are triggered, allowing the cervix to dilate above the physical size of the laminaria. Only one laminaria is required for dilating the cervix with a 10-week pregnancy. As the weeks and the amount of dilatation the pregnancy termination requires progress, more laminaria are inserted and left for longer amounts of time. Most laminaria need at least 4 hours to be useful, but overnight use is indicated in cases that are further along. Successive applications of increased numbers of laminaria can be used for more than 24 hours if the pregnancy is very advanced or if the cervix is unusually rigid.

    Prior to insertion, Betadine preparation of the cervix is performed. Laminaria insertion is simple, often requiring a single toothed tenaculum to stabilize the cervix and no anesthesia. For cases in which several laminaria must be inserted, 12 cc of lidocaine administered paracervically can provide comfort. The patient must understand that laminaria insertion is the beginning of the abortion procedure. Pregnancies have safely been carried to term after laminaria insertion and removal, but late onset intrauterine infection or chorioamnionitis is a concern. Counseling is used to be sure the patient understands her risks once she starts the dilatation process.

    ¡@

  • Failure to dilate: Failure to dilate the cervix is not common, but if no dilators (the smallest is a 3 mm) or laminaria can be admitted, this is the diagnosis. Rare cases exist in which the cervix is so scarred, mostly from previous pregnancies or deliveries, that the os cannot be viewed; the patient may be advised to have a medical abortion. Waiting until the patient is further in pregnancy is an option, as is dilating while watching with sonographic control.

• Intraoperative care of patients undergoing surgical abortion

  ¡@

  • Most patients having an early termination of pregnancy can have their abortion performed under "vocal sedation" (talking the patient through the procedure) as well as local sedation. Most patients do not need an intravenous access for medication.

    ¡@

  • If heavy sedation is selected, then intravenous fluids with lactated Ringer solution or one half normal saline are suitable, at rates appropriate for the patient's age and weight.

    ¡@

  • If a patient is administered intraoperative sedation, appropriate monitoring includes vital sign assessment, assessment of the patient's degree of sedation and responses, and assessment of the patient's pulse oxygen level.

• First trimester surgical abortion

  ¡@

  • Early terminations are performed with little cervical dilatation and using a hand held syringe or a small bore cannula attached to a suction machine. Abortions performed with a syringe are referred to as manual aspirations. Some authors still call them "menstrual extractions," from the days when abortion was more stigmatized and women did not want the procedure referred to as an abortion. Those performed with the suction generated by a vacuum aspirator are referred to as a vacuum aspiration. Both procedures take only a few minutes.

    ¡@

  • Single toothed tenaculums are used to grasp the cervix after it has been prepared with Betadine. Local anesthetic is administered in a paracervical fashion. The agent used is usually lidocaine 1-2% or Nesacaine 1%. No epinephrine is necessary. The local anesthetic takes effect rapidly, and studies of the exact route of administration (several spots around the cervix or at 3 and 9 o'clock) have not shown large differences in efficacy.

    ¡@

  • For gestations of 6 weeks or less, cannulas of 3-6 mm can be used. For gestations of 7-9 weeks, 5-9 mm cannulas are used. The suction cannulas can be soft or rigid, straight or bent, and experienced providers can use either type interchangeably. Both suction syringes and the suction machines generate 60-70 mm Hg of pressure. Performing procedures at lower levels of suction prolongs the procedure and, therefore, increases bleeding and patient discomfort.

    ¡@

  • The amount of tissue obtained correlates with the stage of gestation and the fetal number. The amount of bleeding can be very slight, 5-25 cc for very early terminations, or as heavy as 100-250 cc. Amounts over 200 cc blood loss usually are indicative of uterine atony. Cervical lacerations increase the amount of blood lost.

    ¡@

  • Intravenous sedation with versed 2.5-5 mg can be performed, and rapidly acting narcotics can be supplemented for pain relief. Others have had success with sublingual diazepam, and intramuscular Toradol (ketorolac tromethamine) can be used.

    ¡@

  • Abortions in the late first trimester are performed with or without preoperative cervical dilatation with laminaria or misoprostol. If a woman is multiparous, no preoperative dilatation is usually necessary, although procedures under local anesthetic are more comfortable if the cervix has been prepared.

    ¡@

  • Sounding should be performed with the cannula to protect the uterus against perforation. The actual evacuation is performed by applying suction to the syringe or via the machine. The completeness of the procedure is ensured by the feel of the uterus against the instrument, the sound of the uterine curettage, and the appearance of bubbles in the cannula. Sonographic confirmation of completeness is helpful in some cases. The procedure takes a few minutes to complete, and the estimated blood loss should be minimal (5-10 cc range for very early abortion and 50-100 cc range for later procedures).

    ¡@

  • Tissue inspection for completeness is an essential part of the procedure.

• Dilatation and curettage

  ¡@

  • This specifically is a term that usually is applied to a diagnostic gynecological procedure or the treatment of an incomplete abortion.

    ¡@

  • The procedure usually is accomplished with similar dilatation procedures, but the uterine emptying is accomplished with a sharp metal curette. These curettes are more dangerous than the flexible or rigid plastic devices, which are used in the suction procedures, and are not recommended for abortion procedures.

• Second trimester dilatation and evacuation

  ¡@

  • Dilatation and evacuation is the safest and most common method of second trimester termination for experienced providers. These procedures are accomplished with similar preoperative preparation to first trimester preparation; however, the dilatation must be accomplished over hours and, in some cases, days.

    ¡@

  • The procedure requires the cervix to be dilated to 2-3 cm, admitting at least a #16 Hegar dilator or a size 53 French (Fr) dilator. The cervix is grasped with a single-toothed tenaculum after Betadine preparation. The procedure is accomplished using a combination of suction curettage and manual evacuation of the fetus and placenta. Ultrasonic guidance is valuable, and some providers use manual palpation of the fundus to guide the use of the forceps that are used for evacuation. The forceps are used most carefully in the lower uterine segment. The types of forceps used are Soper, ring, or packing forceps, with Soper forceps being the most useful. Uterotonics can help push the products of conception toward the internal os to facilitate the process.

    ¡@

  • The procedure is longer and more uncomfortable than a first trimester procedure, but many patients can comfortably go through the procedure with local anesthesia. Blood loss for these procedures is in the range of 100-350 cc.

• Dilatation and extraction

  ¡@

  • This procedure is accomplished by cervical preparation similar to cases of dilatation and evacuation, but the fetus is removed in a mostly intact condition. The fetal head is made of cartilage and is able to be collapsed after the contents are evacuated so that it may pass through the cervix.

    ¡@

  • Very few providers perform the procedure. It usually is reserved for cases of maternal medical complications or fetal abnormalities.

    ¡@

  • With an intact fetus, the family may hold their baby and have time to say good-bye as part of the grieving process. Reconstituting the fetal head with a jellied substance can restore fetal anatomy.

    ¡@

  • The procedure also has been referred to as intact dilatation and extraction and has been called "partial birth abortion" by abortion opponents.

• Induction of labor

  ¡@

  • Most physicians have experience with the standard Pitocin protocols for labor induction, and these can be used in the case of a second trimester of pregnancy.

    ¡@

  • Premature rupture of membranes is one indication for this method.

    ¡@

  • Research generally indicates better success with prostaglandin methods, and this method typically is not employed.

• Hysterotomy

  ¡@

  • Hysterotomy is reserved for very few cases. Large uterine leiomyomata has been an indication for hysterotomy in the performance of an abortion, and in the past, placental previa was another indication (recent reports have shown that a dilatation and evacuation procedure can be performed safely in some of these cases).

    ¡@

  • The uterine segment is never developed well enough to place the incision there, so virtually all hysterotomies must be performed by classic uterine incisions.

• Hysterectomy: Very few indications exist for the use of hysterectomies to terminate pregnancies. The extra uterine vasculature that develops in pregnancy makes hysterectomy more dangerous, and the incidence of hemorrhage and complications rises.

• Surgical sterilization: Bilateral tubal ligation via minilaparotomy, tubal fulguration, or tubal device occlusion is easily performed at the time of first or second trimester abortion of pregnancy. Failure rates are high because of the enlarged tubal structure and lumen, but the magnitude of risk is not well established.

Consultations: The counseling process should offer referrals for those who need ongoing support.

Diet: Patients may eat a regular diet.

Activity:

• Tampons, douche, and intercourse should be avoided for one week.

• Heavy activity or lifting should be avoided for a few days.

MEDICATION

¡@

The procedure usually is performed under local anesthesia. For those modestly tolerant of pain, either intravenous sedation or administration of a preoperative antianxiolytic agent can be used. Narcotics can be used for pain control but usually are not necessary. A variety of agents may be useful for contracting the uterus postprocedure, although in a typical first trimester procedure, none are necessary. Agents useful to control bleeding include Pitocin, Methergine, or prostaglandins. Mechanical devices to control hemorrhage can be useful as well, which typically consists of intrauterine insertion of a Foley catheter.

Postprocedure pain and cramping are effectively treated with a variety of analgesic agents (ie, NSAIDs, Tylenol, codeine, Vicodin).

Dinoprostone (Cervidil, Prepidil, Prostin E2) is a prostaglandin administered vaginally and is approved specifically for the use at term in labor for cervical preparation. It works almost as well as misoprostol, but it is very expensive and not used for abortions for this reason alone.
¡@

Drug Category: Local anesthetics -- A few patients can tolerate cervical dilatation and suction curettage with no anesthesia and also through relaxation techniques. Paracervical blockade provides some additional cervical compliance in the dilatation phase as well as all the anesthetic that is necessary for early abortion procedures.

Drug Name ¡@	Lidocaine (Xylocaine) -- Used for paracervical block during procedure to keep patient comfortable. Local anesthetic blocks nerve impulses by decreasing sodium influx across neuronal cell membranes. Alternatively, chloroprocaine (Nesacaine) may be used.
Adult Dose	Popular mixture used (12-20 mL in divided doses to be injected in each patient): (1) 50 mL vial of 1% or 0.5% lidocaine and draw off 5 mL (2) add 2-4 U (0.1 mL) of vasopressin (3) add 5 mL of buffer (8.4% sodium bicarbonate) If Atropine is added, dose is 2 mg/50 mL Deep injections are more efficacious than superficial, inject 10-15 mL halfway between the os and the periphery of the cervix at 4 sites (12, 3, 6, 9 o'clock) at a depth of 0.75-1 inch
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity; Adams-Stokes or Wolf-Parkinson-White syndrome; SA, AV, or intraventricular heart if artificial pacemaker is not in place
Interactions	Increased toxicity with cimetidine, beta-blockers; additive cardiodepressant action with procainamide, tocainide; increases effects of succinylcholine
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Associated with malignant hyperthermia; increased risk of CNS and cardiac adverse effects in the elderly; seizures, heart block, and AV conduction abnormalities have occurred; caution with heart failure, hepatic disease, hypoxia, hypovolemia, shock, respiratory depression, and bradycardia

Drug Category: Prostaglandins -- Abortifacient drugs of various types can be used for medical termination or treatment of ectopic pregnancy. Rarely they are used to complete an incomplete surgical abortion. This class of drugs includes misoprostol, gemeprost, and PG05 (15MF2 alpha prostaglandin).

Drug Name ¡@	Misoprostol (Cytotec) -- Not approved for use in pregnancy, yet is an invaluable medication widely used for cervical preparation for abortion, labor induction, and as a medical abortifacient. Provides safe, passive method of cervical dilatation and should be considered for preabortion ripening when prior uterine surgery (ie, LEEP, C-section) are known risk factors for uterine perforation during surgical abortion. Can be administered orally or vaginally. Some studies show premoistening tablets placed vaginally helps absorption. Patients can be instructed in self-administration to help time the dose in synchrony with their abortion procedure. In a study by Singh of primigravid women (6-11 wk gestation), 93.3% achieved dilatation of the cervix of 8 mm or greater after 3 h postintravaginal misoprostol 400 mcg, whereas only 16.7% of women achieved this after 2 h of 600 mcg. The 600-mcg group had slightly greater adverse effects (eg, bleeding, abdominal pain, fever >38ºC). Dosage intended for cervical ripening can induce abortion in some patients. Oral doses of 100-400 mcg can be combined with vaginal insertion of prostaglandins to enhance cervical dilatation.
Adult Dose	Cervical ripening: 25-100 mcg (vaginally) for term pregnancies, lower doses may need to be repeated q4-6h Termination: 200-800 mcg, most patients do not need repeat dosing for 24 h
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity; pregnancy not intended for termination; glaucoma; sickle cell anemia; hypotension; mitral stenosis
Interactions	Antacids containing magnesium may increase diarrhea
Pregnancy	X - Contraindicated in pregnancy
Precautions	Inform patient of potential adverse effects (eg, GI distress, cramping, bleeding); GI distress slightly greater with oral administration.

Drug Category: Antiprogesterones -- Antiprogesterone class of drugs for medical termination of pregnancy are used. Other potential uses include postcoital contraception, leiomyomatas, endometriosis, endometrial cancer, breast cancer, ovarian cancer, glaucoma, myomas, and Cushing syndrome. Antiprogesterones do not effectively treat ectopic pregnancy and should not be used for this indication.

Drug Name ¡@	Mifeprex (RU-486) -- Progesterone receptor antagonist, which has 5 times greater affinity for the receptor than progesterone. By blocking progesterone, the hormone that maintains pregnancy, abortion can be completed. Cervix is softened and dilated; decidual necrosis and detachment of the pregnancy at the endometrium and uterine contractions ensue.
Adult Dose	600 mg PO day 1 of medical abortion regimen; doses as low as 200 mg reported as efficacious
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity; confirmed/suspected ectopic pregnancy; undiagnosed adnexal mass; IUD in place; chronic adrenal failure; concurrent long-term corticosteroid therapy; hemorrhagic disorders; concurrent anticoagulation therapy; inherited porphyrias
Interactions	Not studied yet; possibly ketoconazole, itraconazole, erythromycin, grapefruit juice; rifampin, dexamethasone, St John's Wort, some anticonvulsants
Pregnancy	X - Contraindicated in pregnancy
Precautions	Abdominal pain, uterine cramping, nausea, vomiting, diarrhea

Drug Category: Antimetabolites -- The antimetabolite, methotrexate, has been used for over 15 years for the medical treatment of early, unruptured ectopic pregnancies. Success rate for this indication is greater than 90%. Adverse effects are minimal and regimens are cost effective. This offers effective destruction of rapidly dividing placental cells. This class of drug to be used for the medical termination of pregnancy, although for complete expulsion, it usually has to be administered in conjunction with prostaglandin.

Drug Name ¡@	Methotrexate (Folex PFS, Rheumatrex) -- Antimetabolite that works by blocking enzyme dihydrofolate reductase, thereby inhibiting folate production and, thus, DNA synthesis. Primarily affects rapidly dividing cells first, such as trophoblast cells.
Adult Dose	50 mg/m2 IM; alternatively, 50 mg PO
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity; alcoholism; hepatic insufficiency; kidney disease; inflammatory bowel disease; clotting disorder; documented immunodeficiency syndromes; preexisting blood dyscrasias; bone marrow hypoplasia; leukopenia, thrombocytopenia; significant anemia (Hct<30%)
Interactions	Oral aminoglycosides may decrease absorption and blood levels of concurrent oral methotrexate (MTX); charcoal lowers MTX levels; coadministration with etretinate may increase hepatotoxicity of MTX; folic acid or its derivatives contained in some vitamins may decrease response to MTX Probenecid, NSAIDs, salicylates, procarbazine, and sulfonamides, including TMP-SMZ, can increase MTX plasma levels; may decrease phenytoin plasma levels; may increase plasma levels of thiopurines
Pregnancy	D - Unsafe in pregnancy
Precautions	Nausea, vomiting, diarrhea, hot flushes, headache, cramping, dizziness; toxic adverse effects on the hematologic, renal, GI, pulmonary, and neurological systems

Drug Category: Uterotonics -- The rapid and complete emptying of the uterus usually provides a natural uterine contraction process that successfully halts postabortion blood loss and eventually leads to normal uterine blood loss and normal uterine involution back to the prepregnant state. The uterotonic medications typically are used to enhance this process or to halt immediate postabortion bleeding. In some cases, these drugs can be potent enough inducers of uterine activity to lead to abortion without other drugs or regimens.

Drug Name ¡@	Oxytocin (Pitocin) -- Produces rhythmic uterine contractions and can stimulate the gravid uterus as well as vasopressive and antidiuretic effects. Can also control postpartum bleeding or hemorrhage. When used as in labor protocols, can induce second trimester abortion.
Adult Dose	10 U IM after delivery Alternatively, 10-40 U IV in 1000 mL of IV fluid at rate high enough to control uterine atony
Pediatric Dose	>12 years: Administer as in adults
Contraindications	Documented hypersensitivity; cardiac arrhythmias with tachycardia
Interactions	Pressor effect of sympathomimetics may increase when used concomitantly with oxytocic drugs, causing postpartum hypertension
Pregnancy	X - Contraindicated in pregnancy
Precautions	Overstimulated uterus can be hazardous; hypertonic contractions can occur in a patient whose uterus is hypersensitive to oxytocin, regardless of whether it was administered appropriately; oxytocin has intrinsic antidiuretic effect that, when administered by continuous infusion and patient is receiving fluids by mouth, can cause water intoxication

Drug Category: Ergot Alkaloids -- Also in the category of uterotonics and almost exclusively used for treatment of postabortal bleeding, atony, or hemorrhage.

Drug Name ¡@	Methylergonovine (Methergine) -- Acts directly on uterine smooth muscle, causing a sustained tetanic uterotonic effect that reduces uterine bleeding and shortens third stage of labor. Administer IM during puerperium, delivery of placenta, or after delivering anterior shoulder. Also may be administered IV, over no less than 60 sec, but should not be administered routinely because it may provoke hypertension or a cerebrovascular accident. Monitor BP closely when administering IV.
Adult Dose	0.2 mg PO tid/qid for 2-7 d Alternatively, 0.2 mg IM/IV repeat q2-4h prn
Pediatric Dose	<12 years: Not established >12 years: Administer as in adults
Contraindications	Documented hypersensitivity; glaucoma; Tourette syndrome; anxiety; hypertension
Interactions	Concurrent administration of methylergonovine with vasoconstrictors or other ergot alkaloids may produce additive effect
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Caution in sepsis, obliterative vascular disease, or hepatic or renal insufficiency

Drug Name ¡@	Carboprost tromethamine (Hemabate) -- Prostaglandin similar to F2-alpha (dinoprost) but has longer duration and produces myometrial contractions that induce hemostasis at placentation site, which reduces postpartum bleeding.
Adult Dose	250 mcg IM; repeat at 15-90 min intervals to maximum dose of 2 mg
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity; pelvic inflammatory disease
Interactions	Increases toxicity of oxytocic agents
Pregnancy	X - Contraindicated in pregnancy
Precautions	Caution in cardiovascular disease, asthma, hypotension or hypertension, adrenal disease, diabetes, renal or hepatic disease, a compromised uteri, or jaundice; do not inject IV (may induce hypertension and bronchospasm)

Drug Category: Sedatives -- During surgical abortion, relaxation techniques and local anesthetic is typically all that is required to adequate pain relief. In some patients, the use of intravenous, oral, or sublingual sedatives can enhance this effect.

Drug Name ¡@	Midazolam (Versed) -- Shorter-acting benzodiazepine sedative-hypnotic useful in patients requiring acute and/or short-term sedation. Also useful for its amnestic effects.
Adult Dose	0.5-2 mg IV over 2 min; repeat q2-3min prn; total IV dose generally 2.5-5 mg
Pediatric Dose	>12 years: 0.5 mg IV over 2 min; repeat q3-4min prn
Contraindications	Documented hypersensitivity; preexisting hypotension; narrow-angle glaucoma; sensitivity to propylene glycol (diluent)
Interactions	Sedative effects of midazolam may be antagonized by theophyllines; narcotics and erythromycin may accentuate sedative effects of midazolam due to decreased clearance
Pregnancy	D - Unsafe in pregnancy
Precautions	Caution in congestive heart failure, pulmonary disease, renal impairment, and hepatic failure; Romazicon is a benzodiazepine antagonist used to reverse the effects of versed (0.2-0.3 mg IV, may wear off faster than the versed itself)

Drug Category: Antiemetics -- Antiemetics are not typically necessary unless patients already have pre-existing nausea and vomiting of pregnancy or have nausea and vomiting in reaction to general anesthesia.

Drug Name ¡@	Prochlorperazine (Compazine) -- May relieve nausea and vomiting by blocking postsynaptic mesolimbic dopamine receptors through anticholinergic effects and depressing reticular activating system.
Adult Dose	5-10 mg PO/IM tid/qid; not to exceed 40 mg/d 2.5-10 mg IV q3-4h prn; not to exceed 10 mg/dose or 40 mg/d 25 mg PR bid
Pediatric Dose	2.5 mg PO/PR q8h or 5 mg q12h prn; not to exceed 15 mg/d IV dosing is not recommended for children 0.1-0.15 mg/kg/dose IM and change to PO as soon as possible
Contraindications	Documented hypersensitivity; bone marrow suppression; narrow-angle glaucoma; severe liver or cardiac disease
Interactions	Coadministration with other CNS depressants or anticonvulsants may cause additive effects; with epinephrine, may cause hypotension
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Drug-induced Parkinson syndrome or pseudoparkinsonism occurs quite frequently; akathisia is most common extrapyramidal reaction in elderly; lowers seizure threshold; caution with history of seizures

Drug Name ¡@	Promethazine (Phenergan) -- Antidopaminergic agent effective in treating emesis. Blocks postsynaptic mesolimbic dopaminergic receptors in brain and reduces stimuli to brainstem reticular system.
Adult Dose	12.5-25 mg PO/IV/IM/PR q4h prn
Pediatric Dose	0.25-1.0 mg/kg PO/IV/IM/PR 4-6 times/d prn
Contraindications	Documented hypersensitivity; narrow-angle glaucoma
Interactions	May have additive effects when used concurrently with other CNS depressants or anticonvulsants; coadministration with epinephrine may cause hypotension
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Caution in cardiovascular disease, impaired liver function, seizures, sleep apnea, and asthma; avoid accidental intra-arterial injections

Drug Category: Antibiotics -- Most antibiotics are used prophylactically to prevent postoperative endometritis. Some institutions have used dosages that would cover CT and GC because patients are often unavailable for contact after an abortion (lack of providers means many travel very far to receive their abortion).

Drug Name ¡@	Doxycycline (Vibramycin) -- Inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Prophylaxis of postabortion infections. If contraindicated, use erythromycin or ampicillin. Suspected cervicitis for chlamydia.
Adult Dose	New ACOG recommendations recommend 100 mg PO 1 h prior to abortion, then 200 mg PO postabortion; this regimen may produce nausea and vomiting 100 mg PO bid for 1-3 d postabortion
Pediatric Dose	2-5 mg/kg/d in 1-2 divided doses; not to exceed 200 mg/d, not generally applicable
Contraindications	Documented hypersensitivity; severe hepatic dysfunction
Interactions	Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy
Pregnancy	D - Unsafe in pregnancy
Precautions	Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last one-half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines

Drug Name ¡@	Erythromycin (E-Mycin, Ery-tab, Eryc, Erythrocin) -- Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections. Prophylaxis of postabortion infections. Use if doxycycline is contraindicated.
Adult Dose	333 mg PO tid for 3-7 d; alternatively 500 mg PO bid for 3-7 d
Pediatric Dose	30-50 mg/kg/d (15-25 mg/lb/d) PO divided q6-8h
Contraindications	Documented hypersensitivity; hepatic impairment; concomitant use of astemizole, cisapride, pimozide, terfenadine
Interactions	Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin, increases risk of rhabdomyolysis
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI adverse effects are common (administer doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur; pseudomembranous colitis

Drug Category: Immune globulins -- Pregnancies past 5 weeks of gestation may have an established fetal blood system and Rh sensitization can occur without administration. Typically, no preadministration antibody screens are performed in this patient population.

Drug Name ¡@	Rh0(D) immune globulin (RhoGAM) -- Given to Rh(-) mothers to avoid sensitization to Rh(+) fetal blood.
Adult Dose	<12 wk gestation: 50 mcg (minidose) >12 wk gestation: 300 mcg Administered up to 72 h postabortion
Pediatric Dose	Adolescent: Administer as in adults
Contraindications	Documented hypersensitivity
Interactions	None
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Anaphylactic shock; fever; do not administer live virus vaccine within 3 mo

Drug Name ¡@	Metronidazole (Flagyl) -- Recommended as an alternative for endometritis prophylaxis.
Adult Dose	500 mg tid for 7d postabortion when allergic to doxycycline; stat when treating suspected bacterial vaginosis prior to abortion.
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity
Interactions	May increase toxicity of anticoagulants, lithium, and phenytoin; cimetidine may increase toxicity of metronidazole; disulfiram reaction may occur with orally ingested ethanol
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Adjust dose in hepatic disease; monitor for seizures and development of peripheral neuropathy

FOLLOW-UP

¡@

Further Inpatient Care:
¡@

• Termination of pregnancy never requires inpatient treatment. If the patient has a medical condition that requires hospitalization, then that condition's indications for hospitalization should be followed.

• Patients that must have their termination performed by hysterotomy or hysterectomy are hospitalized according to the needs of their operation.

• Patients with a medical complication of pregnancy termination, such as a perforation, are cared for according to the treatment necessary.

• For the patient who has a fundal perforation, with an instrument that is not connected to suction, patient observation may be indicated but usually is not necessary.

• Patients with perforations suspicious of bowel injury may need exploratory surgery via laparoscopy (if the physician is an extremely experienced laparoscopist) or an exploratory laparotomy. If these procedures are used, hospitalization may be required for 1-3 days to manage the usual postoperative course.

• Antibiotic prophylaxis is recommended for any additional surgery with broad-spectrum antibiotic coverage administered over at least 24 hours.

Further Outpatient Care:
¡@

• Postoperative care of a patient after surgical abortion

• Observe patients for a half an hour, checking for abdominal pain, unusual bleeding, and observing vital signs.

• Anti-D immunoglobulin should be administered on the day of the procedure to patients who are Rh-negative.

• Patients selecting immediate intrauterine device (IUD) insertion, depot-medroxyprogesterone acetate (DMPA), or Norplant may begin their contraceptive this day as well.

  ¡@

• Postoperative appointments are usually 1-3 weeks after the procedure and are important to ensure timely involution, confirm the pregnancy termination has been completed, evaluate the patient for medical complications, offer continuing contraceptive care, and evaluate psychological status.

• Postoperatively, patients should be given instructions to contact their providers if they have severe pain, run a fever of 100.4ºF or higher, or soak through more than 4-5 pads per hour or more than 12 pads in 24 hours. The first 24 hours, a nonaspirin analgesic, such as acetaminophen, is recommended, and after that time, patients can switch to a nonsteroidal anti-inflammatory drug (NSAID), such as ibuprofen or naproxen.

  ¡@

• Provide patients with emergency contact numbers and instructions regarding where to present if they have an emergency and cannot reach the provider.

• Patients may bleed very little, if at all, if they were very early in gestation, but the most common bleeding pattern is to have bleeding the day of the procedure, then not much until the fifth postoperative day when heavier cramping and clotting occurs.

  ¡@

• Patients should not use tampons for 5 days and should not have intercourse until bleeding has stopped for a week or they have been cleared by their provider at their postoperative visit.

• With antibiotic use as prophylaxis, postabortion infection rates in most population groups should be less than 1-2%. Antibiotic use for the procedure usually is limited to the day of the procedure or a 2-3 day course. The antibiotics used are typically broad spectrum, and most centers use doxycycline 100 mg bid, with erythromycin for those who are allergic. If bacterial vaginosis is discovered, then the use of Flagyl 500 mg bid or Cleocin 300 mg bid PO is selected. Some providers with caseloads of patients who come from far distances and are difficult to locate postoperatively may select to administer longer antibiotic courses to cover the event of a positive CT or GC test coming back after the patient has left the facility and either cannot be or does not want to be contacted.

  ¡@

• Most oral contraceptive pills can be started the day of the procedure or the following Sunday. IUDs can be inserted that day or with the next menstrual period. DMPA shots can be given that day or up to 5 days later.

• Patients who have had their pregnancies terminated need a postoperative evaluation in 1-3 weeks. Women should be offered a contact number for any questions, and episodes of unusual pain or bleeding should be cause for an early postoperative visit.

• Uterine perforation: If the patient had a fundal perforation with no suction applied, then observation for a few hours and evaluation of hemoglobin levels is standard of care.

• Evaluation of acute abdominal pain postabortion: Suspect acute hematometra, retained products of conception, pelvic infection, or perforation with or without bowel involvement.

In/Out Patient Meds:
¡@

• Antibiotic therapy

• Uterotonics

• Analgesia

• Antiemetics

• Antianxiolytics

• Oral contraceptives

• Long-term steroid contraception

Deterrence/Prevention:
¡@

• Effective contraception is the only reasonable strategy toward abortion prevention. Since the introduction of the long-acting steroid contraceptives, abortion rates in the US have steadily declined.

Complications:
¡@

• Uterine hemorrhage

  ¡@

  • Hemorrhage has been defined in a variety of ways; the need for transfusion is exceedingly rare. If uterine hemorrhage rates include hemorrhage immediately postabortion, uterine atony rates of hemorrhage are as low as 5%. Initial hemorrhage should be evaluated by ensuring complete uterine evacuation.

    ¡@

  • The next steps are typically medical: the use of intramuscular Methergine 0.2 mg, the use of intravenous Pitocin drips with 10-20 mIU/L running at 100-200 cc. Hemabate also is helpful.

    ¡@

  • In the past, uterine packing has been used, but this can be accomplished effectively with the intrauterine inflation of a Foley balloon. Five cc balloons can be inflated with 30 cc, or 30 cc balloons can be inflated with up to almost 100 cc of sterile saline. The inflation should correlate with uterine size.

    ¡@

  • Uterine artery embolization can be used if placenta accreta is encountered, but very few of these procedures have been performed, and statistical success rates are impossible to evaluate.

• Uterine perforation

  ¡@

  • Perforation rates have been estimated to occur in 1 per 250 cases. They usually are fundal and recognized by the provider at the time of the procedure. In a study by Pridmore of 13,907 women who underwent outpatient termination of pregnancy, the perforation rate was 0.05%, and in the second trimester, procedures from 13-20 weeks, the perforation rate was 0.32%.

    ¡@

  • Risk factors for perforation are previous terminations of pregnancy, lower segment cesarean sections, and loop electrosurgical excision procedures (LEEPs) of the cervix. The common denominator is thought to be scarring of the internal cervical os.

    ¡@

  • Fundal perforations only require observation. If the extent of the perforation cannot be determined, if the patient is medically unstable, if the suction was applied at the time of the perforation, or if bowel or fat content was obtained by forceps at the time of a perforation, surgical evaluation of the patient is necessary. The surgical evaluation may be performed by an experienced laparoscopist or by laparotomy.

• Retained products of conception

  ¡@

  • Evaluation of the obtained products of conception at the time of abortion and postabortion uterine scanning have reduced the retained products of conception rate to less than 1% of cases, and in one series reported by Hakim, Tovell, and Burnhill of 170,000 cases, only 0.5% incidence occurred in the first trimester. In cases of second trimester abortions, retained tissue rates are even lower with rates of 0.2% according to Peterson and 0.5% according to Kafrissen et al.

    ¡@

  • Cases of delayed bleeding even after a normal cycle have been reported. Dilatation and curettage or hysteroscopy are necessary if bleeding is brisker or if the amount of tissue is determined by sonography to warrant more extensive procedures. Endometrial color flow can be helpful in determining retained tissue.

• Endometritis and pelvic inflammatory disease

  ¡@

  • Infections postabortion are rare, occurring in fewer than 1% of cases. These usually are due to preexisting infections, such as bacterial vaginosis, cervicitis or salpingitis, or a failure of antibiotic prophylaxis.
  • The usual criteria for the diagnosis of pelvic inflammatory disease (PID) should be used.

• Coexistent ectopic pregnancy

  ¡@

  • Residual positive HCG titers are not uncommon, and clinicians need to be vigilant in their evaluation of persistent positive pregnancy tests in order to avoid missing an ectopic pregnancy.

    ¡@

  • Pelvic ultrasonography is the most helpful tool. Presence of significant tenderness on postoperative exam, a history of continued pain, and increasing or plateauing HCG titers should make a clinician suspicious. Coexistent interactive and extrauterine pregnancies are observed only in extremely rare cases.

• Asherman syndrome

  ¡@

  • Postabortion uterine synechiae (or adhesions) that can obliterate part or all of the endometrial cavity have been reported. This is thought to be more likely secondary to endometritis than the instrumentation of the uterus, but sharp curetting after the abortion procedure should be avoided to avoid denuding the basal layer of the endometrium.

    ¡@

  • The diagnosis is made by hysteroscopy or hysterosalpingogram in a patient who presents with postabortion amenorrhea.

• Delayed sequelae

• Few long-term sequelae of abortions have been documented. Although a syndrome of posttraumatic stress has been reported, the literature has not been able to separate the stressors of the patient's social situation that lead to the abortion from the abortion procedure itself.

  ¡@

• Initial studies seemed to indicate a greater risk of elective termination than that of term birth. Most of these data have been refuted. In the Iowa Women's Health Study, women aged 55-64 years had their health records of the state linked with the national Cancer Institute's Surveillance, Epidemiology and End Results Program (SEER). Only 1.8% of the women in this study reported induced abortion, which is lower than other age groups will be as they reach that age, but the relative risk of breast cancer for those with prior induced abortion was 1.1%. These results must be reevaluated over time.

  ¡@

• One recent article reported a slightly greater incidence of adenomyosis postabortion. A study by Zhou of 15,727 women who had induced abortions compared with 46,026 women who did not have induced abortions showed an increased risk in preterm and postterm pregnancy after induced abortion. Another study by Hendricks showed that both induced abortion and prior cesarean section increased the risk of placenta previa. In women with 3 prior cesarean sections, the relative risk was 2.4 and the risk of having 2 or more previous abortions was 2.1.

  ¡@

• In another study by Eras, abortion was suggested as a protective factor against the development of preeclampsia in a subsequent pregnancy in women with no prior deliveries.

• Psychologic consequences of abortion

  ¡@

  • Generally, the psychological health of the abortion patient parallels her psychologic health prior to seeking an abortion. If the woman needed to have the abortion in secrecy, then long-term psychologic sequelae, such as intrusive thoughts, are more common.

    ¡@

  • Many studies actually have demonstrated improved psychological well-being after abortion. For the studies that have shown this, the improvement in psychological health is suspected to be more reflective of the patient dealing with the social issues that led her to select abortion to begin with.

    ¡@

  • Sometimes, confusion over normal emotions, such as sadness and grief versus psychological illnesses (eg, depression), seems to occur. The most common feeling experienced after an abortion is that of relief and confidence in the decision. Few women may experience feelings of grief and guilt postabortion, and these feelings usually pass within days to weeks in most cases and do not lead to psychological sequelae. One study demonstrated that the risk for serious psychiatric illness postabortion was 1%, whereas with live birth it was 10%. Few studies on these data exist, partly because studies performed earlier gave no indication for psychiatric sequelae so no new findings have been researched. Considering that over 1.5 million abortions are performed in the US each year, if an epidemic of psychiatric sequelae due to the procedure occurred, it would be observed by now.

    ¡@

  • Many confounding factors are involved in a women's emotional status during the time of her abortion. Relationships, religion, age, social support, and previous psychological stability all play a part.

    ¡@

  • An entire new set of circumstances and feelings exist in cases of rape and incest. These are often psychologically complex situations and unique to each case.

• Providers can help women through abortions by presenting options and explaining the procedures. Counseling with a trained professional occurs before the abortion. This is a good time to identify factors that might lead to a patient having difficult feelings after the abortion. Some factors are low self-esteem, preexisting or past psychological illness, lack of emotional support, and past childhood sexual abuse. The counselor can then confront these issues before the procedure and help the patient assess specific needs and improve coping strategies.

Prognosis:
¡@

• Fertility is not impaired. Prognosis is excellent.

Patient Education:
¡@

• Give patients information about abortion and how to care for themselves postabortion.

• Educate patients about birth control options, and discuss when to start birth control postabortion.

MISCELLANEOUS

¡@

• ¡@
  • Parental consent
  • Most young adolescents have parental or family involvement in their decision to have an abortion. Adolescents who are older, especially those living independently, often do not. In spite of ample scientific evidence that the majority of teens seek parental involvement and widespread legal concern that individuals who do not seek parental involvement may be at risk physically or emotionally, a barrage of legislation mandates that all minors seek parental consents or that the parents be notified in advance of a minor child having an abortion.

    ¡@

  • The laws that have enabled this to occur legally are backed in the Supreme Court. By 1999, 38 states had such laws, and 29 states enforce their laws. Currently only Connecticut, Maine, and the District of Columbia have laws that affirm the rights of a minor to seek her own abortion. As a result, abortion providers in states that do not require parental consent for minors have begun to see adolescents that may travel hundreds of miles to seek an abortion.
  • ¡@
  • Mandatory waiting periods
  • Mandatory waiting periods mandate by law that the woman seeking to terminate a pregnancy must first, in person, receive specific information about the pregnancy and pregnancy alternatives.
  • In spite of the fact that these laws typically only mandate a short 24-hour waiting period, they have the effect of increasing the percentage of second trimester abortions in states with these laws.

  Special Concerns:
  ¡@

  • The abortion debate
  • Advances in neonatal medicine with improved fetal survival very early in gestation have fueled the abortion debate in the past 2 decades, overshadowing the continued cultural debate on beginning of life.
  • Recently, the progress in using fetal tissue, fetal stem cells, or even discarded embryos for research and medical treatments has kept the debate both vocal and contentious. These therapies may be indicated in the treatment of diabetes, Parkinson disease, kidney disease, and cartilage diseases, among others.
  • Current national regulations prohibit most fetal tissue research, but the National Institute of Health (NIH) revealed late in the year 2000 that it will allow stem cell research.
  • Many world cultures place a premium on male children, and reports of selective abortion of female fetuses have continued to surface.
  • Provider issues
  • Most abortion providers are obstetricians and gynecologists. However, providers from a variety of backgrounds (family practitioners, nurses) can be taught to perform abortions safely. Physicians generally are receptive to the concept of legal abortions being available in the US. Epidemiologic research shows those most receptive tend to be non-Catholic and trained in a residency program where abortion observation was a requirement.
  • Keeping abortions safe, legal, and rare are the goals of abortion providers.
  • As providers have decreased in number, women are traveling farther to obtain abortions, presenting later in pregnancy, and are unable to obtain services if they are poor and live in most rural areas.
  • Posttraumatic stress has been reported in abortion workers exposed to violent abortion protests at their clinics.
  • ¡@

  BIBLIOGRAPHY

  ¡@

  • Acharya PS, Gluckman SJ: Bacteremia following placement of intracervical laminaria tents. Clin Infect Dis 1999 Sep; 29(3): 695-7[Medline].
  • Aiyer AN, Ruiz G, Steinman A: Influence of physician attitudes on willingness to perform abortion. Obstet Gynecol 1999 Apr; 93(4): 576-80[Medline].
  • Baird DT: Mode of action of medical methods of abortion. J Am Med Womens Assoc 2000; 55(3 Suppl): 121-6[Medline].
  • Bartholomew LL, Grimes DA: The alleged association between induced abortion and risk of breast cancer: biology or bias? Obstet Gynecol Surv 1998 Nov; 53(11): 708-14[Medline].
  • Berer M: Making abortions safe: a matter of good public health policy and practice. Bull World Health Organ 2000; 78(5): 580-92[Medline].
  • Bernick BA, Ufberg DD, Nemiroff R: Success rate of cytogenetic analysis at the time of second-trimester dilation and evacuation. Am J Obstet Gynecol 1998 Oct; 179(4): 957-61[Medline].
  • Blanchard K, Winikoff B, Ellertson C: Misoprostol used alone for the termination of early pregnancy. A review of the evidence. Contraception 1999 Apr; 59(4): 209-17[Medline].
  • Borgatta L, Burnhill M, Haskell S: Instituting medical abortion services: changes in outcome and acceptability related to provider experience. J Am Med Womens Assoc 2000; 55(3 Suppl): 173-6[Medline].
  • Breitbart V, Repass DC: The counseling component of medical abortion. J Am Med Womens Assoc 2000; 55(3 Suppl): 164-6[Medline].
  • Christin-Maitre S, Bouchard P, Spitz IM: Medical termination of pregnancy. N Engl J Med 2000 Mar 30; 342(13): 946-56[Medline].
  • Clark S, Ellertson C, Winikoff B: Is medical abortion acceptable to all American women: the impact of sociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion. J Am Med Womens Assoc 2000; 55(3 Suppl): 177-82[Medline].
  • Cole DS, Bruck LR: Anaphylaxis after laminaria insertion. Obstet Gynecol 2000 Jun; 95(6 Pt 2): 1025[Medline].
  • Cook RJ, Dickens BM: Human rights and abortion laws. Int J Gynaecol Obstet 1999 Apr; 65(1): 81-7[Medline].
  • Coyaji K: Early medical abortion in India: three studies and their implications for abortion services. J Am Med Womens Assoc 2000; 55(3 Suppl): 191-4[Medline].
  • Creinin MD: Medical abortion regimens: historical context and overview. Am J Obstet Gynecol 2000 Aug; 183(2 Suppl): S3-9[Medline].
  • Creinin MD, Pymar HC: Medical abortion alternatives to mifepristone. J Am Med Womens Assoc 2000; 55(3 Suppl): 127-32, 150[Medline].
  • Creinin MD, Spitz IM: Use of various ultrasonographic criteria to evaluate the efficacy of mifepristone and misoprostol for medical abortion. Am J Obstet Gynecol 1999 Dec; 181(6): 1419-24[Medline].
  • Creinin MD: Conception rates after abortion with methotrexate and misoprostol. Int J Gynaecol Obstet 1999 May; 65(2): 183-8[Medline].
  • Creinin MD, Wiebe E, Gold M: Methotrexate and misoprostol for early abortion in adolescent women. J Pediatr Adolesc Gynecol 1999 May; 12(2): 71-7[Medline].
  • Creinin MD, Jerald H: Success rates and estimation of gestational age for medical abortion vary with transvaginal ultrasonographic criteria. Am J Obstet Gynecol 1999 Jan; 180(1 Pt 1): 35-41[Medline].
  • Davis A, Westhoff C, De Nonno L: Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. J Am Med Womens Assoc 2000; 55(3 Suppl): 141-4[Medline].
  • Dobie SA, Hart LG, Glusker A: Abortion services in rural Washington State, 1983-1984 to 1993-1994: availability and outcomes. Fam Plann Perspect 1999 Sep-Oct; 31(5): 241-5[Medline].
  • Drey EA, Thomas LJ, Benowitz NL: Safety of intra-amniotic digoxin administration before late second-trimester abortion by dilation and evacuation. Am J Obstet Gynecol 2000 May; 182(5): 1063-6[Medline].
  • Elimian A, Verma U, Tejani N: Effect of causing fetal cardiac asystole on second-trimester abortion. Obstet Gynecol 1999 Jul; 94(1): 139-41[Medline].
  • Elul B, Pearlman E, Sorhaindo A: In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol. J Am Med Womens Assoc 2000; 55(3 Suppl): 169-72[Medline].
  • Epner JE, Jonas HS, Seckinger DL: Late-term abortion. JAMA 1998 Aug 26; 280(8): 724-9[Medline].
  • Eras JL, Saftlas AF, Triche E: Abortion and its effect on risk of preeclampsia and transient hypertension. Epidemiology 2000 Jan; 11(1): 36-43[Medline].
  • Evans MI, Goldberg JD, Horenstein J: Selective termination for structural, chromosomal, and mendelian anomalies: international experience. Am J Obstet Gynecol 1999 Oct; 181(4): 893-7[Medline].
  • Fitzpatrick KM, Wilson M: Exposure to violence and posttraumatic stress symptomatology among abortion clinic workers. J Trauma Stress 1999 Apr; 12(2): 227-42[Medline].
  • Fong YF, Singh K, Prasad RN: Severe hyperthermia following use of vaginal misoprostol for pre-operative cervical priming. Int J Gynaecol Obstet 1999 Jan; 64(1): 73-4[Medline].
  • Geva E, Fait G, Yovel I: Second-trimester multifetal pregnancy reduction facilitates prenatal diagnosis before the procedure. Fertil Steril 2000 Mar; 73(3): 505-8[Medline].
  • Gouk EV, Lincoln K, Khair A: Medical termination of pregnancy at 63 to 83 days gestation. Br J Obstet Gynaecol 1999 Jun; 106(6): 535-9[Medline].
  • Grimes D, Schulz K, Stanwood N: Immediate post-abortal insertion of intrauterine devices. Cochrane Database Syst Rev 2000; (2): CD001777[Medline].
  • Grimes DA: A 26-year-old woman seeking an abortion. JAMA 1999 Sep 22-29; 282(12): 1169-75[Medline].
  • Hellberg D, Mogilevkina I, Mardh PA: Sexually transmitted diseases and gynecologic symptoms and signs in women with a history of induced abortion. Sex Transm Dis 1999 Apr; 26(4): 197-200[Medline].
  • Hendricks MS, Chow YH, Bhagavath B: Previous cesarean section and abortion as risk factors for developing placenta previa. J Obstet Gynaecol Res 1999 Apr; 25(2): 137-42[Medline].
  • Henshaw SK: Abortion incidence and services in the United States, 1995-1996. Fam Plann Perspect 1998 Nov-Dec; 30(6): 263-70, 287[Medline].
  • Jain JK, Meckstroth KR, Park M: A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception 1999 Dec; 60(6): 353-6[Medline].
  • Jain JK, Meckstroth KR, Mishell DR: Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol. Am J Obstet Gynecol 1999 Dec; 181(6): 1386-91[Medline].
  • Jain JK, Kuo J, Mishell DR: A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Obstet Gynecol 1999 Apr; 93(4): 571-5[Medline].
  • Jensen JT, Harvey SM, Beckman LJ: Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study. Am J Obstet Gynecol 2000 Jun; 182(6): 1292-9[Medline].
  • Jensen MP, Miller L, Fisher LD: Assessment of pain during medical procedures: a comparison of three scales. Clin J Pain 1998 Dec; 14(4): 343-9[Medline].
  • Jermy K, Oyelese O, Bourne T: Uterine anomalies and failed surgical termination of pregnancy: the role of routine preoperative transvaginal sonography. Ultrasound Obstet Gynecol 1999 Dec; 14(6): 431-3[Medline].
  • Jones BS, Heller S: Providing medical abortion: legal issues of relevance to providers. J Am Med Womens Assoc 2000; 55(3 Suppl): 145-50[Medline].
  • Joyce T, Kaestner R: The impact of Mississippi's mandatory delay law on the timing of abortion. Fam Plann Perspect 2000 Jan-Feb; 32(1): 4-13[Medline].
  • Kahn JG, Becker BJ, MacIsaa L: The efficacy of medical abortion: a meta-analysis. Contraception 2000 Jan; 61(1): 29-40[Medline].
  • Koenig JD, Tapias MP, Hoff T: Are US health professionals likely to prescribe mifepristone or methotrexate? J Am Med Womens Assoc 2000; 55(3 Suppl): 155-60[Medline].
  • Koonin LM: Abortion reporting in the era of medical procedures: why is it important? J Am Med Womens Assoc 2000; 55(3 Suppl): 203-4[Medline].
  • Kruse B: Advanced practice clinicians and medical abortion: increasing access to care. J Am Med Womens Assoc 2000; 55(3 Suppl): 167-8[Medline].
  • Larsson PG, Platz-Christensen JJ, Dalaker K: Treatment with 2% clindamycin vaginal cream prior to first trimester surgical abortion to reduce signs of postoperative infection: a prospective, double-blinded, placebo-controlled, multicenter study. Acta Obstet Gynecol Scand 2000 May; 79(5): 390-6[Medline].
  • Lazovich D, Thompson JA, Mink PJ: Induced abortion and breast cancer risk. Epidemiology 2000 Jan; 11(1): 76-80[Medline].
  • Levgur M, Abadi MA, Tucker A: Adenomyosis: symptoms, histology, and pregnancy terminations. Obstet Gynecol 2000 May; 95(5): 688-91[Medline].
  • Major B, Gramzow RH: Abortion as stigma: cognitive and emotional implications of concealment. J Pers Soc Psychol 1999 Oct; 77(4): 735-45[Medline].
  • Mansfield C, Hopfer S, Marteau TM: Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: a systematic literature review. European Concerted Action: DADA (Decision-making After the Diagnosis of a fetal Abnormality). Prenat Diagn 1999 Sep; 19(9): 808-12[Medline].
  • Martin CW, Brown AH, Baird DT: A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary. Contraception 1998 Aug; 58(2): 99-103[Medline].
  • Miller VL, Ransom SB, Shalhoub A: Multifetal pregnancy reduction: perinatal and fiscal outcomes. Am J Obstet Gynecol 2000 Jun; 182(6): 1575-80[Medline].
  • Owen J, Hauth JC: Vaginal misoprostol vs. concentrated oxytocin plus low-dose prostaglandin E2 for second trimester pregnancy termination. J Matern Fetal Med 1999 Mar-Apr; 8(2): 48-50[Medline].
  • Paul M, Schaff E, Nichols M: The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice. Am J Obstet Gynecol 2000 Aug; 183(2 Suppl): S34-43[Medline].
  • Paul M, Lichtenberg ES, Borgatta L: A Clinician's Guide to Medical and Surgical Abortion . New York, NY Churchill Livingstone; 1999.
  • Perry KG, Rinehart BK, Terrone DA: Second-trimester uterine evacuation: A comparison of intra-amniotic (15S)-15-methyl-prostaglandin F2alpha and intravaginal misoprostol. Am J Obstet Gynecol 1999 Nov; 181(5 Pt 1): 1057-61[Medline].
  • Pridmore BR, Chambers DG: Uterine perforation during surgical abortion: a review of diagnosis, management and prevention. Aust N Z J Obstet Gynaecol 1999 Aug; 39(3): 349-53[Medline].
  • Rosenblatt RA, Robinson KB, Larson EH: Medical students' attitudes toward abortion and other reproductive health services. Fam Med 1999 Mar; 31(3): 195-9[Medline].
  • Schaff EA, Fielding SL: A comparison of the Abortion Rights Mobilization and Population Council trials. J Am Med Womens Assoc 2000; 55(3 Suppl): 137-40[Medline].
  • Schaff EA, Fielding SL, Eisinger SH: Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception 2000 Jan; 61(1): 41-6[Medline].
  • Schaff EA, Fielding SL, Westhoff C: Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMA 2000 Oct 18; 284(15): 1948-53[Medline].
  • Schuler L, Pastuszak A, Sanseverino TV: Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol 1999 Mar-Apr; 13(2): 147-51[Medline].
  • Selam B, Lembet A, Stone J: Pregnancy complications and neonatal outcomes in multifetal pregnancies reduced to twins compared with nonreduced twin pregnancies. Am J Perinatol 1999; 16(2): 65-71[Medline].
  • Selam B, Torok O, Lembet A: Genetic amniocentesis after multifetal pregnancy reduction. Am J Obstet Gynecol 1999 Jan; 180(1 Pt 1): 226-30[Medline].
  • Shanahan MA, Metheny WP, Star J: Induced abortion. Physician training and practice patterns. J Reprod Med 1999 May; 44(5): 428-32[Medline].
  • Singh K, Ratnam SS: The influence of abortion legislation on maternal mortality. Int J Gynaecol Obstet 1998 Dec; 63 Suppl 1: S123-9[Medline].
  • Stephen JA, Timor-Tritsch IE, Lerner JP: Amniocentesis after multifetal pregnancy reduction: is it safe? Am J Obstet Gynecol 2000 Apr; 182(4): 962-5[Medline].
  • Trussell J, Ellertson C: Estimating the efficacy of medical abortion. Contraception 1999 Sep; 60(3): 119-35[Medline].
  • Westfall JM, Sophocles A, Burggraf H: Manual vacuum aspiration for first-trimester abortion. Arch Fam Med 1998 Nov-Dec; 7(6): 559-62[Medline].
  • WHO: Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. BJOG 2000 Apr; 107(4): 524-30[Medline].
  • Wiebe ER: Comparing abortion induced with methotrexate and misoprostol to methotrexate alone. Contraception 1999 Jan; 59(1): 7-10[Medline].
  • Wu S: Medical abortion in China. J Am Med Womens Assoc 2000; 55(3 Suppl): 197-9, 204[Medline].
  • Zhou W, Sorensen HT, Olsen J: Induced abortion and subsequent pregnancy duration. Obstet Gynecol 1999 Dec; 94(6): 948-53[Medline].